Malte H Wehmeyer1, Sabine Jordan1, Stefan Lüth1, Johannes Hartl1, Albrecht Stoehr2, Christiane Eißing1, Ansgar W Lohse3, Jörg Petersen2, Peter Buggisch2, Julian Schulze Zur Wiesch4. 1. I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany. 2. Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany. 3. I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany. 4. I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany. Electronic address: j.schulze-zur-wiesch@uke.de.
Abstract
BACKGROUND: There are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients. AIMS: To evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection. METHODS: All HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N=24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N=63). RESULTS: The demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7±9.0 years and 42.0±9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P=0.003). Fatigue (P=0.007), flu-like (P=0.015), gastrointestinal (P<0.001), dermatologic (P<0.001) and psychiatric symptoms (P=0.022) were more common in the control group. CONCLUSIONS: In our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.
BACKGROUND: There are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients. AIMS: To evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection. METHODS: All HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N=24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N=63). RESULTS: The demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7±9.0 years and 42.0±9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P=0.003). Fatigue (P=0.007), flu-like (P=0.015), gastrointestinal (P<0.001), dermatologic (P<0.001) and psychiatric symptoms (P=0.022) were more common in the control group. CONCLUSIONS: In our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.
Authors: Delphine Degré; Thomas Sersté; Luc Lasser; Jean Delwaide; Peter Starkel; Wim Laleman; Philippe Langlet; Hendrik Reynaert; Stefan Bourgeois; Thomas Vanwolleghem; Sergio Negrin Dastis; Thierry Gustot; Anja Geerts; Christophe Van Steenkiste; Chantal de Galocsy; Antonia Lepida; Hans Orlent; Christophe Moreno Journal: PLoS One Date: 2017-01-26 Impact factor: 3.240